Unlocking the Untapped Potential of Photoresponsive Dual‐Gas Nanomedicine in Glaucoma Therapy
Advanced Healthcare Materials · 2025
DOI: 10.1002/adhm.202404245 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2025. Verfasst von Jiamin Liu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Eye Institute and Department of Ophthalmology, Eye & ENT Hospital, Fudan University, NHC Key Laboratory of Myopia and Related Eye Diseases, Key Labor…. Hauptthemen laut MEDLINE: Glaucoma, Nanomedicine, Gases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 49 Literaturangaben. Gefördert von: National Natural Science Foundation of China, General project of Shanghai Natural Science Foundation, Medical Engineering Joint Fund of Fudan University.
Abstract (Originalsprache)
Glaucoma, a leading cause of irreversible blindness worldwide, is characterized by optic nerve damage often associated with elevated intraocular pressure (IOP). Although gas therapies hold promise for glaucoma treatment, the limitations of single‐gas strategies constrain their therapeutic efficacy. Here, a photoresponsive dual‐gas nanomedicine is developed for targeted glaucoma therapy. The nanomedicine, PdH‐D‐S, is engineered by synthesizing mesoporous palladium hydride (meso‐PdH) with efficient hydrogen (H₂) storage capacity and abundant pore channels, followed by surface modification with DSPE‐mPEG and loading sodium nitroprusside (SNP) as a nitric oxide (NO) donor. PdH‐D‐S penetrates the cornea to reach IOP‐regulating tissues, including the trabecular meshwork and Schlemm's canal. Upon 808 nm laser excitation, PdH‐D‐S releases H₂ and NO in a controlled manner. H₂ activates the AKT/p‐AKT/eNOS/sGC signaling pathway, while NO binds to soluble guanylate cyclase (sGC), converting guanosine triphosphate (GTP) to cyclic guanosine monophosphate (cGMP), relaxing trabecular meshwork cells and enhancing aqueous humor outflow. This dual‐gas system demonstrates high therapeutic efficacy in lowering IOP and offers a mechanistic advancement in glaucoma treatment through synergistic gas therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Eye Institute and Department of Ophthalmology, Eye & ENT Hospital, Fudan University, NHC Key Laboratory of Myopia and Related Eye Diseases, Key Laboratory of Myopia and Related Eye Diseases, Chinese Academy of Medical S…
- State Key Laboratory of Rare Earth Resource Utilization, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, Jilin, 130022, China.
- University of Science and Technology of China, Hefei, Anhui, 230026, China.
ORCID-Profile: Yuan Lei
Förderung
- National Natural Science Foundation of China
- General project of Shanghai Natural Science Foundation
- Medical Engineering Joint Fund of Fudan University
- Jilin Province Youth Science and Technology Talent support project
- Program of Science and Technology Development Plan of Jilin Province of China
Zitieren
APA
Liu, J., Liang, Y., Tian, Y., Sun, X., Lei, Y., Lei, P., & Zhang, H. (2025). Unlocking the Untapped Potential of Photoresponsive Dual‐Gas Nanomedicine in Glaucoma Therapy. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202404245
Vancouver
Liu J, Liang Y, Tian Y, Sun X, Lei Y, Lei P, et al. Unlocking the Untapped Potential of Photoresponsive Dual‐Gas Nanomedicine in Glaucoma Therapy. Advanced Healthcare Materials. 2025. doi:10.1002/adhm.202404245
BibTeX
@article{Liu2025,
author = {Liu, Jiamin and Liang, Yuan and Tian, Yi and Sun, Xinghuai and Lei, Yuan and Lei, Pengpeng and Zhang, Hongjie},
title = {Unlocking the Untapped Potential of Photoresponsive Dual‐Gas Nanomedicine in Glaucoma Therapy},
journal = {Advanced Healthcare Materials},
year = {2025},
doi = {10.1002/adhm.202404245}
}
EUVIMED